{"id":63120,"date":"2025-03-26T09:46:07","date_gmt":"2025-03-26T09:46:07","guid":{"rendered":"https:\/?p=63120"},"modified":"2025-03-26T09:46:07","modified_gmt":"2025-03-26T09:46:07","slug":"is-cardiol-therapeutics-crdlca-a-buy-analyst-ratings-ahead-of-q4-earnings","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/is-cardiol-therapeutics-crdlca-a-buy-analyst-ratings-ahead-of-q4-earnings\/","title":{"rendered":"Is Cardiol Therapeutics (CRDL:CA) a Buy? Analyst Ratings Ahead of Q4 Earnings"},"content":{"rendered":"

Cardiol Therapeutics Inc (CRDL:CA)<\/a> is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart diseases.<\/p>\n

The company’s lead product, CardiolRx, is an oral cannabidiol formulation under clinical development for various heart conditions.<\/p>\n

Before we dive in, we have a special offer! For a limited time, you can get 70% off Stock Target Advisor\u2019s premium features. Claim your discount<\/a> here!<\/p>\n

\"Spring<\/p>\n

Expected Quarterly Earnings Report of Cardiol Therapeutics Inc:<\/h2>\n

Cardiol Therapeutics is anticipated to release its financial results for the fourth quarter of 2024 on March 27, 2025. Analyst estimates suggest an expected loss per share of CAD 0.127 for this quarter.<\/p>\n

Looking ahead, the company is projected to report a loss per share of CAD 0.130 for the first quarter of 2025, with the earnings release scheduled for May 20, 2025.<\/p>\n

\"\"<\/a><\/p>\n

Stock Target Advisor’s Analysis on Cardiol Therapeutics Inc:<\/h2>\n

Analyst<\/a> consensus indicates a “Moderate Buy” rating for Cardiol Therapeutics, based on evaluations from two analysts. The average one-year price target is CAD 6.88, with forecasts ranging from a low of CAD 5.94 to a high of CAD 8.00.\u00a0 These projections suggest a significant potential upside from the current trading price.<\/p>\n

Conclusion:<\/h2>\n

Cardiol Therapeutics Inc. continues to advance its clinical programs targeting heart diseases, with upcoming earnings reports expected to provide further insights into the company’s financial health and operational progress.<\/p>\n

Analyst projections and ratings reflect optimism about the company’s future performance, indicating potential growth opportunities for investors.<\/p>\n","protected":false},"excerpt":{"rendered":"

Cardiol Therapeutics Inc (CRDL:CA) is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart diseases. The company’s lead product, CardiolRx,…<\/p>\n","protected":false},"author":17,"featured_media":63123,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-63120","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"acf":[],"yoast_head":"\nIs Cardiol Therapeutics (CRDL:CA) a Buy? Analyst Ratings Ahead of Q4 Earnings<\/title>\n<meta name=\"description\" content=\"With Q4 earnings near, analysts rate CRDL:CA a \u201cModerate Buy.\u201d Learn why investors are watching this biotech stock closely.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.stocktargetadvisor.com\/blog\/is-cardiol-therapeutics-crdlca-a-buy-analyst-ratings-ahead-of-q4-earnings\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Is Cardiol Therapeutics (CRDL:CA) a Buy? Analyst Ratings Ahead of Q4 Earnings\" \/>\n<meta property=\"og:description\" content=\"With Q4 earnings near, analysts rate CRDL:CA a \u201cModerate Buy.\u201d Learn why investors are watching this biotech stock closely.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/is-cardiol-therapeutics-crdlca-a-buy-analyst-ratings-ahead-of-q4-earnings\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-26T09:46:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2025\/03\/STAs-Blog-Images-2025-03-26T143107.170.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1800\" \/>\n\t<meta property=\"og:image:height\" content=\"942\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Muzzammil Ahmad\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@https:\/\/x.com\/Muzzammil625\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Muzzammil Ahmad\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/is-cardiol-therapeutics-crdlca-a-buy-analyst-ratings-ahead-of-q4-earnings\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/is-cardiol-therapeutics-crdlca-a-buy-analyst-ratings-ahead-of-q4-earnings\/\"},\"author\":{\"name\":\"Muzzammil Ahmad\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\"},\"headline\":\"Is Cardiol Therapeutics (CRDL:CA) a Buy? Analyst Ratings Ahead of Q4 Earnings\",\"datePublished\":\"2025-03-26T09:46:07+00:00\",\"dateModified\":\"2025-03-26T09:46:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/is-cardiol-therapeutics-crdlca-a-buy-analyst-ratings-ahead-of-q4-earnings\/\"},\"wordCount\":244,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"articleSection\":[\"Market News & Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/is-cardiol-therapeutics-crdlca-a-buy-analyst-ratings-ahead-of-q4-earnings\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/is-cardiol-therapeutics-crdlca-a-buy-analyst-ratings-ahead-of-q4-earnings\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/is-cardiol-therapeutics-crdlca-a-buy-analyst-ratings-ahead-of-q4-earnings\/\",\"name\":\"Is Cardiol Therapeutics (CRDL:CA) a Buy? Analyst Ratings Ahead of Q4 Earnings\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2025-03-26T09:46:07+00:00\",\"dateModified\":\"2025-03-26T09:46:07+00:00\",\"description\":\"With Q4 earnings near, analysts rate CRDL:CA a \u201cModerate Buy.\u201d Learn why investors are watching this biotech stock closely.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/is-cardiol-therapeutics-crdlca-a-buy-analyst-ratings-ahead-of-q4-earnings\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/is-cardiol-therapeutics-crdlca-a-buy-analyst-ratings-ahead-of-q4-earnings\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/is-cardiol-therapeutics-crdlca-a-buy-analyst-ratings-ahead-of-q4-earnings\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Is Cardiol Therapeutics (CRDL:CA) a Buy? Analyst Ratings Ahead of Q4 Earnings\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\",\"name\":\"Muzzammil Ahmad\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"caption\":\"Muzzammil Ahmad\"},\"description\":\"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/\",\"https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625\"],\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Is Cardiol Therapeutics (CRDL:CA) a Buy? Analyst Ratings Ahead of Q4 Earnings","description":"With Q4 earnings near, analysts rate CRDL:CA a \u201cModerate Buy.\u201d Learn why investors are watching this biotech stock closely.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.stocktargetadvisor.com\/blog\/is-cardiol-therapeutics-crdlca-a-buy-analyst-ratings-ahead-of-q4-earnings\/","og_locale":"en_US","og_type":"article","og_title":"Is Cardiol Therapeutics (CRDL:CA) a Buy? Analyst Ratings Ahead of Q4 Earnings","og_description":"With Q4 earnings near, analysts rate CRDL:CA a \u201cModerate Buy.\u201d Learn why investors are watching this biotech stock closely.","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/is-cardiol-therapeutics-crdlca-a-buy-analyst-ratings-ahead-of-q4-earnings\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_published_time":"2025-03-26T09:46:07+00:00","og_image":[{"width":1800,"height":942,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2025\/03\/STAs-Blog-Images-2025-03-26T143107.170.png","type":"image\/png"}],"author":"Muzzammil Ahmad","twitter_card":"summary_large_image","twitter_creator":"@https:\/\/x.com\/Muzzammil625","twitter_site":"@AdvisorTarget","twitter_misc":{"Written by":"Muzzammil Ahmad","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/is-cardiol-therapeutics-crdlca-a-buy-analyst-ratings-ahead-of-q4-earnings\/#article","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/is-cardiol-therapeutics-crdlca-a-buy-analyst-ratings-ahead-of-q4-earnings\/"},"author":{"name":"Muzzammil Ahmad","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8"},"headline":"Is Cardiol Therapeutics (CRDL:CA) a Buy? Analyst Ratings Ahead of Q4 Earnings","datePublished":"2025-03-26T09:46:07+00:00","dateModified":"2025-03-26T09:46:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/is-cardiol-therapeutics-crdlca-a-buy-analyst-ratings-ahead-of-q4-earnings\/"},"wordCount":244,"commentCount":0,"publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"articleSection":["Market News & Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.stocktargetadvisor.com\/blog\/is-cardiol-therapeutics-crdlca-a-buy-analyst-ratings-ahead-of-q4-earnings\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/is-cardiol-therapeutics-crdlca-a-buy-analyst-ratings-ahead-of-q4-earnings\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/is-cardiol-therapeutics-crdlca-a-buy-analyst-ratings-ahead-of-q4-earnings\/","name":"Is Cardiol Therapeutics (CRDL:CA) a Buy? Analyst Ratings Ahead of Q4 Earnings","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2025-03-26T09:46:07+00:00","dateModified":"2025-03-26T09:46:07+00:00","description":"With Q4 earnings near, analysts rate CRDL:CA a \u201cModerate Buy.\u201d Learn why investors are watching this biotech stock closely.","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/is-cardiol-therapeutics-crdlca-a-buy-analyst-ratings-ahead-of-q4-earnings\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/is-cardiol-therapeutics-crdlca-a-buy-analyst-ratings-ahead-of-q4-earnings\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/is-cardiol-therapeutics-crdlca-a-buy-analyst-ratings-ahead-of-q4-earnings\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Is Cardiol Therapeutics (CRDL:CA) a Buy? Analyst Ratings Ahead of Q4 Earnings"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]},{"@type":"Person","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8","name":"Muzzammil Ahmad","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","caption":"Muzzammil Ahmad"},"description":"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.","sameAs":["https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/","https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625"],"url":"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/"}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/63120","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/17"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=63120"}],"version-history":[{"count":1,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/63120\/revisions"}],"predecessor-version":[{"id":63124,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/63120\/revisions\/63124"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media\/63123"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=63120"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/categories?post=63120"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/tags?post=63120"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}